Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date18 Mar 1985 |
/ Not yet recruitingPhase 4IIT 24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK. A Prospective, open study of 3 months duration. - HERO
/ Unknown statusNot ApplicableIIT Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection - Ozurdex in post-occlusive macular edema
/ Unknown statusNot ApplicableIIT Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients - ND
100 Clinical Results associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
0 Patents (Medical) associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
100 Deals associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca
100 Translational Medicine associated with Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca